alphaveZYDUSLIFE₹1,118.50

Zydus Lifesciences Ltd.

₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.13L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	0.51	0.56	17.04	17.04
Return on Assets	13.57	12.56	9.78	9.78
Return on Capital Employed	19.30	21.81	19.26	19.26
Return on Invested Capital	16.58	19.72	15.45	14.20
Margins
EBITDA Margin	27.54	30.37	31.22	29.09
Operating Margin	23.64	26.43	26.03	26.03
Incremental Operating Margin	—	41.21	23.66	—
Pretax Margin	24.60	25.93	24.39	21.01
Net Income Margin	20.32	20.10	18.87	16.06
Net Income to Common Margin	0.58	0.63	18.56	15.78
FCF Margin	11.88	21.79	-4.71	-4.71
Additional
Effective Tax Rate	20.33	23.43	24.09	25.22
Dvd Payout Ratio	15.63	6.47	21.59	—
Sustainable Growth Rate	0.43	0.52	13.36	17.04
Incremental Operating Margin %	41.21	23.66	-32.96	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.